• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

6,785
2,304
2,237
1,864
1,727

COUNTRY

1,033
871
272
254
210

CATEGORIES

  • 858
  • 186
  • 679
  • 1,127
  • 398
  • 270
  • 255
  • 66
  • 382
  • 725
  • 1,339
  • 1,356
  • 626
  • 884
  • 1,706
  • 2,689
  • 507
  • 732
  • 0
  • 93

PRICE

7,471
12,545
20,252
26,480

PUBLISHED

2,902
3,771
8,291
26,480

PRODUCT TYPE

21,606
2,901
872
827
164
44
21
21
17
6
1

Pharmaceuticals

The pharmaceutical industry has been for decades one of the most profitable worldwide. Serious challenges, such as the expiry of long-term lucrative patents (Lipitor, to mention just one) and the cuts in healthcare and R&D in many countries worldwide, can pose a challenge to the growth of the industry. Which drug can save the life of the pharmaceutical industry? Highly differentiated strategies: this is what companies should focus on now if they want to stay competitive. Do you want to know more?

You can get a detailed picture of the market and refine your marketing, brand, and sales strategies with the reliable, up-to-date business information provided by the extensive range of reports, books and subscriptions listed under Research and Markets’ Pharmaceuticals category. They cover markets, companies (big Pharma, mid-sized specialty pharmaceutical companies, generic manufacturers, and small firms), technologies, e-healthcare, pharmaeconomics, drug discovery, and drug delivery.

The product coverage is huge. It includes OTC drugs as well disorder and goal-specific products related to respiration, oncology, vitamins, cardio, analgesics, central nervous system, generics, immune disorders, and women’s health. Show Less
Read more

PRODUCT TITLE

Mycosis Fungoides - Pipeline Review, H2 2013

Mycosis Fungoides - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Mycosis Fungoides - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

December 2013
FROM

Nephropathy - Pipeline Review, H2 2013

Nephropathy - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Nephropathy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

December 2013
FROM

Food Allergy - Pipeline Review, H2 2013

Food Allergy - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Food Allergy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

December 2013
FROM

General Anxiety Disorder - Pipeline Review, H2 2013

General Anxiety Disorder - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'General Anxiety Disorder - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

December 2013
FROM

Burkholderia Infections - Pipeline Review, H2 2013

Burkholderia Infections - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Burkholderia Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

December 2013
FROM

PharmaPoint: Microvascular Complications of Diabetes - France Drug Forecast and Market Analysis to 2022

PharmaPoint: Microvascular Complications of Diabetes - France Drug Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy,...

December 2013
FROM

PharmaPoint: Microvascular Complications of Diabetes - Italy Drug Forecast and Market Analysis to 2022

PharmaPoint: Microvascular Complications of Diabetes - Italy Drug Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy,...

December 2013
FROM

PharmaPoint: Microvascular Complications of Diabetes - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Microvascular Complications of Diabetes - UK Drug Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy,...

December 2013
FROM

Ranirestat (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022

Ranirestat (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy,...

December 2013
FROM

Optina (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022

Optina (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy,...

December 2013
FROM

Fragile X Syndrome - Pipeline Review, H2 2013

Fragile X Syndrome - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Fragile X Syndrome - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

December 2013
FROM

Shigella Infections (Shigellosis) - Pipeline Review, H2 2013

Shigella Infections (Shigellosis) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Shigella Infections (Shigellosis) - Pipeline Review, H2 2013', provides an overview of the indication’s...

December 2013
FROM

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2013

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2013', provides...

December 2013
FROM

Nasopharyngitis (Common Cold) - Pipeline Review, H2 2013

'Nasopharyngitis (Common Cold) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development for Nasopharyngitis...

December 2013
FROM

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2013

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review,...

December 2013
FROM

Contact Dermatitis - Pipeline Review, H2 2013

Contact Dermatitis - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Contact Dermatitis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

December 2013
FROM

Myotonic Dystrophy - Pipeline Review, H2 2013

Myotonic Dystrophy - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Myotonic Dystrophy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

December 2013
FROM

Chemotherapy Induced Myelosuppression - Pipeline Review, H2 2013

Chemotherapy Induced Myelosuppression - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Chemotherapy Induced Myelosuppression - Pipeline Review, H2 2013', provides an overview of the indication’s...

December 2013
FROM

Pompe Disease - Pipeline Review, H2 2013

Pompe Disease - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Pompe Disease - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

December 2013
FROM

Blood Coagulation - Pipeline Review, H2 2013

Blood Coagulation - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Blood Coagulation - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

December 2013
FROM
Loading Indicator

Our Clients

Our clients' logos